Entero Therapeutics names Jason Sawyer interim CEO

Entero Therapeutics, Inc. reported a leadership change, removing Richard Joel Paolone as Interim Chief Executive Officer and Chairman of the Board on September 3, 2025, without cause and with immediate effect.

Rhea-AI Filing Summary

Entero Therapeutics, Inc. reported a leadership change, removing Richard Joel Paolone as Interim Chief Executive Officer and Chairman of the Board on September 3, 2025, without cause and with immediate effect. The company states that his termination did not involve any disagreement over financial reporting, policies, or practices, and he will remain on the Board as a director.

In connection with this change, the company also ended Mr. Paolone’s February 12, 2025 consulting agreement, effective immediately, with payment in lieu of the contractual notice period. On September 4, 2025, the Board appointed director Jason D. Sawyer as Interim Chief Executive Officer, effective immediately. Sawyer brings decades of alternative investment experience and currently holds multiple finance and board roles at other companies, while his compensation as Interim CEO will be decided later.

Insights

Corporate governance analyst

Entero shifts interim CEO role, but keeps prior leader on the board.

The company removed Richard Joel Paolone as Interim CEO and Chairman, without cause and effective immediately, while explicitly stating there was no disagreement over financial reporting, policies, or practices. This indicates a governance decision or strategic shift rather than an accounting or compliance issue, which can reduce concern about financial integrity.

At the same time, Entero terminated Paolone’s consulting agreement with payment in lieu of the notice period, and appointed existing director Jason D. Sawyer as Interim CEO the next day. The continuity of Paolone as a director and the interim nature of Sawyer’s role suggest a transitional phase in leadership rather than a fully settled long-term structure, and future disclosures will likely provide more clarity on permanent management and compensation.

8-K Event Classification

3 items: 1.02, 5.02, 9.01

3 items

Item 1.02 Termination of a Material Definitive Agreement Business

A significant contract was terminated, which may affect business operations or revenue.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What leadership change did Entero Therapeutics (FWBI) report in this 8-K?

The company removed Richard Joel Paolone as Interim Chief Executive Officer and Chairman of the Board on September 3, 2025, without cause and effective immediately, and he continues to serve as a director.

Did Entero Therapeutics (FWBI) cite any financial reporting issues in removing Richard Joel Paolone?

The company stated that Mr. Paolones termination as Interim CEO and Chairman was not due to any disagreement regarding its financial reporting, policies, or practices.

Who is the new Interim Chief Executive Officer at Entero Therapeutics (FWBI)?

On September 4, 2025, Entero Therapeutics appointed Jason D. Sawyer, already a director on the Board, to serve as Interim Chief Executive Officer, effective immediately.

What happened to Richard Joel Paolones consulting agreement with Entero Therapeutics (FWBI)?

In connection with his removal as Interim CEO and Chairman, the company terminated the February 12, 2025 consulting agreement with Mr. Paolone without cause, effective immediately, and provided payment in lieu of the contractual notice period.

What experience does Jason D. Sawyer bring as Interim CEO of Entero Therapeutics (FWBI)?

Jason D. Sawyer has 32 years of experience in the alternative investment industry, has helped raise more than $5 billion in alternative assets, deployed over US$300 million in early and growth-stage investments, and currently holds senior finance and board roles at several companies.

Has Entero Therapeutics (FWBI) set compensation terms for Jason D. Sawyer as Interim CEO?

The company disclosed that Mr. Sawyers compensation as Interim Chief Executive Officer will be determined at a later time.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 09/09/2025 - 04:59 PM Learn about SEC filing dates

false 0001604191 0001604191 2025-09-09 2025-09-09 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported): September 9, 2025

Entero Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-37853		46-4993860
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

777 Yamato Road, Suite 502 Boca Raton, Florida		33431
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (561) 589-7020

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		ENTO		Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 1.02 Termination of a Material Definitive Agreement

The information set forth in Item 5.02 below regarding the termination of the consulting agreement is incorporated by reference in this Item 1.02.

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Termination of Richard Joel Paolone as Interim Chief Executive Officer and Chairman of the Board

On September 3, 2025, the Board of Directors (the “Board”) of Entero Therapeutics, Inc. (the “Company”) terminated Richard Joel Paolone as Interim Chief Executive Officer of the Company and Chairman of the Board, without cause, effective immediately. Mr. Paolone’s termination is not due to any disagreement with the Company regarding its financial reporting, policies or practices. Mr. Paolone continues to serve as a director on the Board of the Company.

On September 3, 2025, in connection with his termination as Interim Chief Executive Officer and Chairman of the Board, the Company terminated the consulting agreement between the Company and Mr. Paolone, dated February 12, 2025. The termination was without cause, effective immediately, and included payment in lieu of the contractual notice period.

Appointment of Jason D. Sawyer as Interim Chief Executive Officer

On September 4, 2025, Jason D. Sawyer was appointed to serve as Interim Chief Executive Officer of the Company, effective immediately. Mr. Sawyer continues to serve as a director on the Board of the Company.

Jason D. Sawyer is a 32-year veteran of the alternative investment industry and currently serves as General Manager of Access Alternative Group S.A., a Nassau, Bahamas-based venture investment and advisory firm. Over his career, Mr. Sawyer and the firms in which he was a principal have raised more than $5 billion in alternative assets and deployed more than US$300 million in early and growth-stage investments across software, fintech, blockchain, biotech, clean tech, natural resources, health and fitness, energy, and consumer products. His prior roles include Principal at Crane Capital Associates and Head of its Absolute Return Strategies Group and Founding Partner of Candlebrook Capital, which was an early sponsor of best-in-class ABL funds such as Brevet Capital and Third Eye Capital, as well as numerous other brandname private equity and hedge funds. He has also co-founded and financed ventures such as Pacific West Stone, California Fitness, Sanna Health Corp., and Caary Capital. Mr. Sawyer currently serves as Head of Finance and M&A at Quantum BioPharma (Nasdaq: QNTM), is a director of The FUTR Corp. (TSX.V: FTRC), and serves on the board of Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT), where he chairs the compensation committee and is a member of the audit committee.

There are no arrangements or understandings between Mr. Sawyer and any other persons pursuant to which he was selected as an officer of the Company. There are also no family relationships between Mr. Sawyer and any director or executive officer of the Company, and Mr. Sawyer does not have any direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K. Mr. Sawyer’s compensation as Interim Chief Executive Officer will be determined at a later time.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Entero Therapeutics, Inc.
September 9, 2025	By:	/s/ Jason D. Sawyer
	Name:	Jason D. Sawyer
	Title:	Interim Chief Executive Officer